Ipatasertib is a selective (against a panel of 230 kinases) and potent pan-Akt inhibitor (IC50s: Akt1 = 5 nM, Akt2 = 18 nM, Akt3 = 8 nM).1 It displayed efficacy in xenograft models of prostate, breast, ovarian, colorectal, non-small cell lung, glioblastoma, and melanoma cancers.2 In clinical trials.
* VAT and and shipping costs not included. Errors and price changes excepted